中文版English

Home | Add to Favorites | Contact Us

Home >> Department >> Innovation Platform >> Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD St…

Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study

 

The Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study comprise the research groups from the Departments of Drug Metabolism, Pharmacology, and Biosynthesis. The laboratory was established in 2014 and approved by Beijing Science and Technology Commission. Professor Yan Li serves as the director of laboratory. The chairman of the academic committee for the laboratory is Prof. Chang-Xiao Liu (an academician at the Chinese Academy of Engineering), and the vice chairmen are Prof. Guang-Ji Wang (an academician at the Chinese Academy of Engineering) and Prof. Jian-Dong Jiang (Director of the Institute of Materia Medica, Chinese Academy of Medical Sciences). Currently, the laboratory is composed of 22 researchers, including 5 professors, 5 associate professors, 1 senior technician, and 6 lecturers.

The laboratory’s research focuses on establishing and advancing new drugs for the treatment of critical diseases and developing innovative theories and techniques. Using druggability and PK/PD studies, the laboratory aims to study non-clinical drug metabolism and PK/PDs, serving Beijing as well as the rest of China by providing professional technological support to druggability and non-clinical research and boosting development of pharmaceutical industry. The key research interests of the laboratory include the following areas:

1) Druggability based on PK/PD evaluation

2) PK/PD of complex components and active products in natural medicine

3) Development of microbiota metabolism models

4) Regulation and molecular mechanisms of metabolizing enzymes and transporters

5) Novel drug targets and therapeutic mechanisms for critical diseases

       The laboratory has been supported by many prestigious national and local research grants (approximately 46 funding projects), including the “11th Five-Year Plans” and “12th Five-Year Plans” (for a chemical pharmaceutical technology platform, early druggability evaluation and key technology/new drug candidates/pre-clinical study), the National Science Foundation of China, the National “863” projects, and the Key Foundation of Natural Science of Beijing Municipality, et al. In the last five years, the members in the laboratory have published 92 academic articles and 12 monographs, and have filed 37 patents. Twenty-five doctoral and sixteen master students have been instructed and their careers nourished in the laboratory. The laboratory has received myriad distinguished awards, such as the Chinese Medical prize, the first-class Beijing Award for Science and Technology Progress, and the second-class National Award for Science and Technology Progress. In total, 44 drug research and development projects have been conducted during the past five years, with 28 of these projects derived from drug research institutions and enterprises in Beijing.

Drug metabolism is one of the important division of pharmacology in the Institute of Materia Medica, Chinese Academy of Medical Sciences. The subject has been evaluated as a state-level key discipline for many years and has always ranked first in the assessment. Thus far, the study of drug metabolism at the laboratory has cultivated numerous elite academicians.

The Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study integrates major areas of related research, such as drug metabolism, pharmacodynamics, biosynthesis, and pharmaceutical analysis. The laboratory has invested in dedicated researchers and material resources to explore the structure-activity relationships of natural products and their active derivatives, the regulation and molecular mechanisms of metabolizing enzymes and transporters of new drugs, as well as the development of new techniques and methods used in non-clinical drug research. The laboratory, rich in collected experience for drug development, has already made fundamental and strategic contributions and will continue providing strong support for drug research and development throughout Beijing and all of China.